8-K filing — Jaguar Health, Inc. (JAGX)
Filed: 2026-09-04 AccNo: 0001193125-26-383673 Size: 141 KB Item 8.01: Other Events
Stocks · News reference
Jaguar Health Says Findings Of Exploratory Surveys Of Dog Owners And Veterinary Oncologists Support Commercial Opportunity For Neonorm Dog, New Extension Of Jaguar's Neonorm Franchise
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Jaguar Health shares are trading lower. The company announced its Napo unit provided crofelemer for treatment of congenital sodium diarrhea in an infant and said it plans to file for FDA approval for MVID in 2027.
Jaguar Health Says Napo Unit Providing Crofelemer Oral Solution For Compassionate Use In Infant With Intestinal Failure From Congenital Sodium Diarrhea; Plans Mid-2027 NDA Filing For Crofelemer In MVID
Jaguar Health Initiates Commercial Roll Out Of Neonorm Dog
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals.